Ally Financial Inc. Boosts Holdings in Danaher Corporation $DHR

Ally Financial Inc. boosted its position in shares of Danaher Corporation (NYSE:DHR) by 66.7% in the first quarter, HoldingsChannel reports. The fund owned 25,000 shares of the conglomerate’s stock after purchasing an additional 10,000 shares during the quarter. Ally Financial Inc.’s holdings in Danaher were worth $5,125,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after purchasing an additional 194,466 shares in the last quarter. Northern Trust Corp increased its stake in Danaher by 14.3% during the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate’s stock valued at $1,821,477,000 after purchasing an additional 992,594 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Danaher by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate’s stock valued at $1,303,163,000 after purchasing an additional 579,046 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 3.8%

DHR stock opened at $211.7060 on Friday. The firm has a market cap of $151.59 billion, a PE ratio of 45.04, a P/E/G ratio of 2.96 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm’s fifty day moving average is $200.67 and its 200 day moving average is $199.44. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the company posted $1.72 EPS. The company’s revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 23rd. Evercore ISI cut their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Barclays restated an “overweight” rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Robert W. Baird raised their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a report on Friday, July 18th. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.